HC Wainwright & Co. Reiterates Buy on Akero Therapeutics, Maintains $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Akero Therapeutics (NASDAQ:AKRO) and maintained a $40 price target for the company's stock.
November 14, 2023 | 12:25 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Akero Therapeutics with a $40 price target, potentially influencing investor confidence and the stock's performance.
The reiteration of a Buy rating and maintenance of a $40 price target by a reputable analyst could lead to increased investor confidence in Akero Therapeutics, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100